MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.

ABSTRACT:

Background

The myeloid differentiation primary response gene (MYD88) mutation in primary central nervous system lymphomas (PCNSL) may be associated with unfavorable prognosis; however, current evidence remains limited. We aimed to characterize PCNSLs by integration of clinicopathological, molecular, treatment, and survival data.

Methods

We retrospectively identified and validated 57 consecutive patients with PCNSLs according to the 2017 WHO classification of lymphoid neoplasms over 13 years. Formalin-fixed paraffin-embedded tumor samples underwent polymerase chain reaction assay to detect MYD88 mutation. We used Cox regression for survival analysis, including age, treatment, and MYD88 as covariates. We searched the literature for studies reporting

SUBMITTER: Curran OE 

PROVIDER: S-EPMC8349182 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature